<DOC>
	<DOCNO>NCT02146846</DOCNO>
	<brief_summary>The purpose study determine population Pharmacokinetics difference variation pharmacokinetics parameter Imatinib tyrosine kinase inhibitor treatment chronic myeloid leukemia patient Iranian population .</brief_summary>
	<brief_title>Population Pharmacokinetics Imatinib CML Patients Iran</brief_title>
	<detailed_description>patient chronic myeloid leukemia receive Imatinib treatment Iran enter study population pharmacokinetics parameter determine .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>patient chronic phase myeloid leukemia liver renal failure multiple dug treatment previous treatment interferon patient blast accelerate phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cml</keyword>
</DOC>